Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Verve Therapeutics, Inc.

$11.13

-0.01 (-0.09%)

D 28Pipeline Score Richly Valued Biotech · Clinical
Market Cap
992.16 M
EPS
-2.11
P/E Ratio
-
Value Trade
114.94 M
1.09 %
Week
-0.18 %
1 Month
94.58 %
3 Month
39.3 %
6 Month
-62.9 %
5 Year
-62.9 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
10.31 M
52 Week Range
2.86 - 11.41
% held by Insiders
26.23 %
% held by Institutions
73.69 %
Enterprise Value
563.72 M
Total Shares
89.14 M
Short %
27.37 %
Float Shares
65.76 M
Company Description
Founded:2021

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Submission example
VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia and HoFH (program-level regulatory planning)
IND
—

Subscribe to access the data.

CRISPR-Based Gene Editing Therapies
Cardiovascular System
VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia and HoFH (program-level regulatory planning)
IND
—

Subscribe to access the data.

CRISPR-Based Gene Editing Therapies
Cardiovascular System
VERVE-201 (ANGPTL3 Program) Refractory hypercholesterolemia and HoFH (program-level regulatory planning)
IND
—

Subscribe to access the data.

CRISPR-Based Gene Editing Therapies
Cardiovascular System
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
D28
Pipeline Score
$38M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 32%
Micro Cap
(rank 629 of 923)
Percentile Rank
Verve Therapeutics, Inc. faces pipeline headwinds (28/100), with $132M risk-adjusted pipeline value, led by VERVE-201 in Hypercholesterolemia (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
VERVE-201
Small molecule		HypercholesterolemiaPhase 1NCT0645177014% $88M RECRUITING 36 STALLED D (37) Dec 1, 2027 -LOW
Jul 17, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in VERV
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
VERV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VERV ranks across every disease it competes in
Competitive Position is a premium feature
See how VERV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial